Analysed Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE) News Sources
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Tuesday Trading
13-01-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading; Up for Week
30-01-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
02-02-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading; Little Changed for the Week
06-02-2026
yahoo.com
Natuzzi S.p.A. Announces Timing of Its 2026 First Quarter Financial Information and Conference Call
04-08-2026
yahoo.com
Natuzzi Signs Commitment Letter With a Candidate for Chief Executive Officer Role
10-08-2026
yahoo.com
Natuzzi S.p.A. Enters Into a Definitive Agreement With Selected Candidate for Chief Executive Officer Role
20-08-2026
yahoo.com
What is the current price of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE)?
The current price of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE) is $1.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE) absolute price change since previous trading day?
The absolute price change of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE) since the previous trading day is $-0.1484.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE) percentage price change since previous trading day?
The percentage price change of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE) since the previous trading day is -12.9223%.
What is the most recent average sentiment score for Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE)?
The most recent average sentiment score for Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE) is 35 out of 100.
What is the most recent average sentiment for Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE)?
The most recent sentiment for Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE) is .
SEC-8K** Filing Available For Zhangzhou Pientzehuang Pharmaceutical Co Ltd (NTZ:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.